Forbion European Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.50
| IPO Proceeds, $M | $126.50M |
|---|---|
| IPO Date | Dec 10, 2021 |
| CEO | Jasper Bos |
| Left Lead | UBS |
| IPO Cash in Trust | 102.5% |
| SPAC Tenor | 18 + 3 + 3 |
| IPO Sector |
Healthcare
Life sciences industry in Europe |
| IPO Geography | Europe |
| Target Company | enGene |
| Deal Announced | May 17, 2023 |
| Deal Size, $M | $150.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 24, 2023 |
| Amendment Vote | TBD |
| Closing Date | Oct 31, 2023 |
Formerly FRBN
ENGN
ENGNW
| Price | $7.50 |
|---|---|
| Last closing price | $7.52 |
| H/L, 52-week | $17.89 / $43.00 |
| Volume, today | 62,364 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Forbion European Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 23 filings and events
- 2 underwriters
- 5 deal advisors
- 6 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jasper Bos | 46 | CEO and Director |
| Cyril Lesser | 45 | CFO and Director |
| Sander Slootweg | 51 | Director |
| Wouter Joustra | 33 | Director |
| Philip Astley-Sparke | 50 | Director |
| Hilde Steineger | 55 | Director |
| Ton Logtenberg | 63 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| UBS | Joint BR | 8,525,000 | units |
| Kempen & Co. | Joint BR | 2,475,000 | |
| 11,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.